Mah Sing sees property market recovering thestar.com.my - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thestar.com.my Daily Mail and Mail on Sunday newspapers.
“As you know, [our manufacturing business comprises] the existing plastics and gloves, [which] we are also exporting, so this is quite a global market, so we are exploring listing in Hong Kong.” Mah Sing executive director Datuk Steven Ng.
KUALA LUMPUR (Dec 16): Mah Sing Group Bhd is considering listing its manufacturing division which includes its new rubber glove business in Hong Kong.
At a briefing today, Mah Sing executive director Datuk Steven Ng said the group is exploring the listing of its manufacturing division within the next five years.
“As you know, [our manufacturing business comprises] the existing plastics and gloves, [which] we are also exporting, so this is quite a global market, so we are exploring listing in Hong Kong,” Ng said.
Mah Sing diversification into glove manufacturing on track For representational purposes only. – AFPPIX
PETALING JAYA: Mah Sing Group Bhd’s diversification into glove manufacturing remains on track as it has made progress on physical works for its manufacturing facility and regulatory approvals for the venture.
The group reiterated that the targeted April 2021 production date is on schedule, as the installation of glove dipping lines framework and structure is under way.
It anticipates six production lines to be completed in second-quarter 2021 (Q2’21) with an additional six production lines to be completed in Q3’21, translating to a maximum capacity of up to 3.68 billion pieces of gloves per annum.
Bhd are companies leading the charge in the race to supply the Covid-19 vaccine to 32.7 million Malaysians.
Both have fill and finish facilities that have been approved by the National Pharmaceutical Regulatory Authority (NPRA) and are tipped to handle the supply of vaccines that the government purchases.
The priority list for the government is the frontliners and the elderly who are most at risk. That leaves quite a number of people who would want to be inoculated and likely to seek the vaccine from the private healthcare system.
Seizing the opportunity, there are also a host of companies wanting to bring in vaccines to cater to the private sector. From property developers to engineering companies, most are looking at registering the vaccine with the NPRA and distributing it to the private sector.